GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology reported Q3 2026 cash position of $121.7 million with an expected runway extending into mid-2027.
Progress continues toward initiating a Phase 1/2 clinical trial for SC451 in type 1 diabetes as early as late 2026.
Clinical study for SG293 in non-Hodgkin lymphoma is expected to begin in the first quarter of 2027.
A follow-on publication in The New England Journal of Medicine detailed 14-month data showing long-term survival of hypoimmune-modified islet cells (UP421) without immunosuppression.
Strategic collaboration with Mayo Clinic was advanced to accelerate the development of SC451 for type 1 diabetes.
SG227, a CD8-targeted fusosome for multiple myeloma, is advancing with clinical testing expected as early as 2027.
Q3 2026 GAAP net income was $20.4 million ($0.07 per share), contrasting with a net loss of $90.4 million for the nine months ended September 30, 2026.
Research and development expenses totaled $33.9 million for the quarter, driven by higher manufacturing costs for SC451 and SG293.
Non-cash gains of $63.4 million were recognized in Q3 2026 related to changes in the fair value of success payment liabilities and contingent consideration.
General and administrative expenses were $10.9 million for the quarter, primarily due to increased facility costs.
Sana suspended further build-out of its internal manufacturing facility in Bothell, Washington, in favor of utilizing third-party CDMOs.